This trial is active, not recruiting.

Condition lung disease
Treatments nitric oxide for inhalation, nitrogen
Phase phase 3
Sponsor INO Therapeutics
Start date May 2005
End date February 2008
Trial size 800 participants
Trial identifier NCT00551642, EUNO, EU Preemie, INOT27


The purpose of this study is to assess the safety and efficacy of inhaled nitric oxide to reduce the risk of chronic lung disease in pre-term infants with respiratory distress, and to assess the long-term effects of the therapy on the development of these children over 7 years of clinical follow-up.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver)
Primary purpose treatment
24+0-25+6 days weeks gestational age
nitric oxide for inhalation INOmax®
inhaled nitric oxide given at 5 parts per million (ppm) for 7-21 days
nitrogen gas given at 5ppm for 7-21 days
26+0 - 28+6 days weeks Gestational Age
nitric oxide for inhalation INOmax®
inhaled nitric oxide given at 5 parts per million (ppm) for 7-21 days
nitrogen gas given at 5ppm for 7-21 days

Primary Outcomes

Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress
time frame: 36 weeks gestational age
time frame: 36 Weeks GA

Secondary Outcomes

Vital Signs
time frame: Study Duration
Arterial Oxygen Saturation by Pulse Oximetry
time frame: Study Duration
Adverse Events
time frame: Study Duration
Methemoglobin Level
time frame: Baseline, then 24 hours, 2-6 days, Day 7 and Day 14 of treatment

Eligibility Criteria

Male or female participants up to 26 hours old.

Inclusion Criteria: - Inborn preterm infants 24+0 weeks-28+6 days weeks gestational age (defined by first trimester ultrasound or if not available based on the last menstrual period) who requires the use of surfactant within 24 hours of birth (either prophylactically, or for signs of developing respiratory distress), or who requires the use of continuous positive airway pressure (CPAP) (fraction of inspired oxygen concentration (FiO2) ≥ 0.30 on a mean airway pressure ≥ 4cm water (H2O)) within 24 hours of birth in order to maintain an oxygen saturation (SpO2) ≥ 85%. - Informed consent of the guardian. Exclusion Criteria: - Outborn infants. - Infants ≥ 29 weeks gestational age. - Infants requiring FiO2 >0.5 to maintain SpO2 >85%, on a sufficient mean airway pressure (e.g., > 8 cm H2O on controlled mechanical ventilation (CMV)) in order to achieve adequate chest inflation (8-9 ribs on Chest X-ray) two hours after the proper administration of exogenous surfactant. - Any suspected congenital heart disease other than patent ductus arteriosus or atrial septal defect. - Any infant with severe bleeding or coagulation abnormalities at high-risk of diathesis, e.g., platelet <50,000/mm³, fibrinogen <0.5 g/L, other clotting factors <10%. - Any infant in whom a decision has been made not to provide full treatment, e.g., chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc. - Use of another investigational drug or device before or during the active study period.

Additional Information

Official title The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants
Description Although the effects of inhaled Nitric Oxide on pulmonary vascular tone are well-described and relevant to term infants with persistent pulmonary hypertension, the pathophysiology of respiratory failure in preterm infants may be quite different. Chronic lung disease (CLD) represents the final pathway of a heterogeneous group of pulmonary disorders of infancy that usually start in the neonatal period. CLD most commonly occurs in preterm (<30 weeks of gestational age (GA) infants with birth weights less than 1,500 g, and especially in those very preterm (<26 wks GA) with birth weights less than 1,000 g, and who have been treated for respiratory distress syndrome (RDS).
Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by INO Therapeutics.